Avastin (bevacizumab)

Avastin (bevacizumab) is a humanized monoclonal antibody, and was the first commercially available angiogenesis inhibitor. Avastin (bevacizumab) exerts it’s activity by binding to VEGF and preventing VEGF from binding to its receptor, thus inhibiting the angiogenic nature of VEGF.

Target Antigen: VEGF

Vascular endothelial growth factor (VEGF) is also known as VEGF-A and is a signal protein that stimulates vasculogenesis and angiogenesis. The normal function of VEGF is to create new blood vessels for example during embryonic development or after injury. It is a homodimeric, heavily glyscolyated protein of 46 to 48 kDa, with the human form existing in a range of splice variants. As the progression of malignant tumours is highly dependent upon the creation of new blood vessels, VEGF was identified a potential therapeutic target for solid cancers.

Characterization of Bevacizumab Innovator and Biosimilar Products

The Fab-related binding function of Avastin (bevacizumab) allows the antibody to neutralise VEGF by binding with high affinity to the soluble form of VEGF preventing it’s binding to VEGF receptors. A range of binding and cell based potency methods can be employed to characterize Avastin’s Fab-related functions. Avastin can theoretically bind to membrane bound VEGF and the Fc region is theoretically capable of mediating both Complement Dependent Cytotoxicity (CDC) and Antibody Dependent Cellular Cytoxicity (ADCC), however this has not been reported.

BioOutsource provides an integrated characterization and comparability package to support Avastin biosimilar manufacture. Our package includes off-the-shelf binding and bioassays and physicochemical and structural characterization.  In addition to Avastin-specific testing methodologies, we provide an extensive range of generic services to support monoclonal antibody manufacture:

Contact our experts to discuss your Avastin biosimilar testing needs.

Contact a Scientist

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.